Browse > Article
http://dx.doi.org/10.6114/jkood.2022.35.4.106

The Study on the Pityriasis Rosea in Oriental-Western Medicine  

Lee, Kyou-Young (Department of Ophthalmology, Otolaryngology & Dermatology, College of Korean medicine, Sangji University)
Publication Information
The Journal of Korean Medicine Ophthalmology and Otolaryngology and Dermatology / v.35, no.4, 2022 , pp. 106-122 More about this Journal
Abstract
Objectives : In this study, we aimed to analyze the latest knowledge of pityriasis rosea(PR) through oriental-western medical review on PR. Methods : We searched Pubmed, CNKI, and OASIS to select papers related to the cause, mechanism, diagnosis, classification, treatment, and herbal treatment of PR. Results : The results are as follows. 1. Although the exact cause of PR is not known, it has recently been found that reactivation of latent human herpesvirus-6 and human herpesvirus-7 infection is a possible etiology. Most patients require emollients, antihistamines, topical steroids, and macrolides. Acyclovir, and narrow-band UVB therapy are also used. 2. The cause and mechanism of PR in Chinese and Korean medicine can be mainly summarized as wind-heat, blood heat, and blood deficiency and wind-dryness. Most of the herbal medicine used have the effects of clearing heat, cooling the blood, detoxifying, dispelling wind, relieving itching, nourishing blood, and moistening dryness. Conclusions : In Chinese and Korean medicine, it is necessary to organize the representative prescriptions according to pattern identification, and it is also necessary to study the atypical types of PR and its treatment methods. It is thought that research on oriental and western combination therapy should be continuously conducted, and efforts to develop Korean medicine formulations are needed to revitalize clinical research in Korea.
Keywords
Pityriasis rosea; Korean medicine; Review;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Ciccarese G, Parodi A, Drago F. SARS-CoV-2 as possible inducer of viral reactivations. Dermatol Ther. 2020;33(6):e13878.
2 Brambilla L, Maronese CA, Tourlaki A, Veraldi S. Herpes Zoster following COVID-19: a report of three cases. Eur J Dermatol. 2020;30(6):754-6.   DOI
3 Drago F, Ciccarese G, Javor S, Parodi A. Vaccine-induced pityriasis rosea and pityriasis rosea-like eruptions: a review of the literature. J Eur Acad Dermatol Venereol. 2016;30:544,545.
4 Gay JT, Huq M, Gross GP. Herald Patch. Treasure Island (FL):StatPearls Publishing [Internet]. 2022:1-6.
5 Alame MM, Chamsy DJ, Zaraket H. Pityriasis rosea-like eruption associated with ondansetron use in pregnancy. Br J Clin Pharmacol. 2018;84(5):1077-80.   DOI
6 Kwak JY, Lee YH, Shin SH, Ahn JH, Kim MH, Choi IH. Three Cases of Pityriasis Rosea in Child treated with Eunkyo-san. J Korean Med Ophthalmol Otolaryngol Dermatol. 2017;30(2):155-64.
7 Jung MY, Kim MJ, Kim DS, Park YH, Park SY, Kim JH, et al. Pityriasis rosea: Report of 1 Case Treated by Oriental Medicine. J Korean Med Ophthalmol Otolaryngol Dermatol. 2007;20(3):268-75.
8 Drago F, Ciccarese G, Rebora A, Parodi A. Human herpesvirus-6, -7, and Epstein-Barr virus reactivation in pityriasis rosea during COVID-19. J Med Virol. 2021;93(4):1850, 1851.
9 Veraldi S, Spigariolo CB. Pityriasis rosea and COVID-19. J Med Virol. 2021;93(7):4068.   DOI
10 Litchman G, Nair PA, Le JK. Pityriasis Rosea. Treasure Island (FL):StatPearls Publishing[Internet]. 2022:1-7.
11 Gangemi S, Minciullo PL, Guarneri F, Cristani M, Arcoraci T, Spatari G, et al. Increased serum levels of interleukin-22 in patients affected by pityriasis rosea. J Eur Acad Dermatol Venereol. 2009;23:858,859.
12 Dursun R, Temiz SA. The clinics of HHV-6 infection in COVID-19 pandemic: pityriasis rosea and Kawasaki disease. Dermatol Ther. 2020;33(4):e13730.
13 Marcantonio-Santa Cruz OY, Vidal-Navarro A, Pesque D, Gimenez-Arnau AM, Pujol RM, Martin-Ezquerra G. Pityriasis rosea developing after COVID-19 vaccination. J Eur Acad Dermatol Venereol. 2021;35(11):e721,e722.
14 Engelmann I, Ogiez J, Ogiez L, Alidjinou EK, Lazrek M, Dewilde A, et al. Relapsing Pityriasis Rosea With HHV-7 Reactivation in an 11-Year-Old Girl. Pediatrics. 2018;141(5):e20173179.   DOI
15 Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol. 2007;7:179-90.   DOI
16 The society of Korean medicine Ophthalmology, Otolaryngology & Dermatology. Text of Traditional Korean Dermatology & Surgery. Seoul:Globooks. 2022:97-100.
17 Jin HS, Lim HY, Ko WS, Yoon HJ. Herbal Medicine for The Treatment of Pityriasis rosea: A Systematic Review and Meta-analysis. J Korean Med Ophthalmol Otolaryngol Dermatol. 2021;34(4):117-33.
18 Drago F, Broccolo F, Ciccarese G, Rebora A, Parodi A. Persistent pityriasis rosea: an unusual form of pityriasis rosea with persistent active HHV-6 and HHV-7 infection. Dermatology. 2015;230:23-6.   DOI
19 Zhao WC. Clinical study on the treatment of pityriasis rosea with wind-heat and skin retaining method by soothing wind and heat. Master's Thesis of Changchun university of Chinese medicine. 2021:1-58.
20 Jing C. The clinical observation of Tuizhen Xiaoban Decoction in the treatment of wind-heat and blood dry type pityriasis rosea. Master's Thesis of Heilongjiang University of Traditional Chinese Medicine. 2019:1-39.
21 Rodriguez-Zuniga M, Torres N, GarciaPerdomo H. Effectiveness of acyclovir in the treatment of pityriasis rosea. A systematic review and meta-analysis. An Bras Dermatol. 2018;93(5):686-95.   DOI
22 Zawar V, Chuh A. Applicability of proposed diagnostic criteria of pityriasis rosea: Results of a prospective case-control study in India. Indian J Dermatol. 2013;58:439-42.   DOI
23 Drago F, Ciccarese G, Broccolo F, Cozzani E, Parodi A. Pityriasis rosea in children: clinical features and laboratory investigations. Dermatology. 2015;231:9-14.   DOI
24 Drago F, Vecchio F, Rebora A. Use of high-dose acyclovir in pityriasis rosea. J Am Acad Dermatol. 2006;54:82-5.   DOI
25 Vidimos AT, Camisa C. Tongue and cheek: oral lesions in pityriasis rosea. Cutis. 1992;50:276-80.
26 Bjornberg A, Hellgren L. Pityriasis rosea. A statistical, clinical, and laboratory investigation of 826 patients and matched healthy controls. Acta Derm Venereol Suppl (Stockh). 1962;42(suppl 50):1-68.
27 Hall CB, Long CE, Schnabel KC, Caserta MT, McIntyre KM, Costanzo MA, Knott A, Dewhurst S, Insel RA, Epstein LG. Human herpesvirus-6 infection in children. A prospective study of complications and reactivation. N Engl J Med. 1994;331:432-8.   DOI
28 Corson EF, Luscombe HA. Coincidence with pityriasis rosea with pregnancy. AMA Arch Derm Syphilol. 1950;62:562-4.   DOI
29 Drago F, Broccolo F, Zaccaria E, Malnati M, Cocuzza C, Lusso P, et al. Pregnancy outcome in patients with pityriasis rosea. J Am Acad Dermatol. 2008;58:S78-83.   DOI
30 Drago F, Ciccarese G, Rebora A, Parodi A. Pityriasis rosea and pityriasis rosea-like eruption: can they be distinguished? J Dermatol. 2014;41:864,865.
31 Drago F, Broccolo F, Agnoletti A, Drago F, Rebora A, Parodi A. Pityriasis rosea and pityriasis rosea-like eruptions. J Am Acad Dermatol. 2014;70:196.
32 Drago F, Ciccarese G, Javor S, Parodi A. Vaccine-induced pityriasis rosea and pityriasis rosea-like eruptions: a review of the literature. J Eur Acad Dermatol Venereol. 2016;30:544,545.
33 Krishnamurthy K, Walker A, Gropper CA, Hoffman C. To treat or not to treat? Management of guttate psoriasis and pityriasis rosea in patients with evidence of group A Streptococcal infection. J Drugs Dermatol. 2010;9(3):241-50.
34 Jairath V, Mohan M, Jindal N, Gogna P, Syrty C, Monnappa PM, et al. Narrowband UVB phototherapy in pityriasis rosea. Indian Dermatol Online J. 2015;6:326-9.   DOI
35 Yun GJ, Pan F. Clinical application of Yinxieling ointment and pricking cupping bloodletting in treating pityriasis rosea. China's Naturopathy. 2018;9:39-41.
36 Zhang JY. Clinical Observation on Treatment of Blood Heat and Exuberant Wind Type Pityriasis Rosea with Liangjie Xiaozhen Decoction. Master's Thesis of Heilongjiang Academy of Traditional Chinese Medicine. 2019:1-37.
37 Zheng ZG. Clinical Observation on Yinqiao Powder Combined with Western Medicine in the Treatment of Pityriasis Rosea. Chinese Medicine Modern Distance Education of China. 2020;4:250-2.
38 Drago F, Broccolo F, Javor S, Drago F, Rebora A, Parodi A. Evidence of human herpesvirus-6 and 7 reactivation in miscarrying women with pityriasis rosea. J Am Acad Dermatol. 2014;71:198,199.
39 Liu G. Clinical Observation on 12 Cases of Refractory Pityriasis Rosea Treated by Integrated Traditional Chinese and Western Medicine. China's Naturopathy. 2019;3:60,61.
40 Geo JS, Liu TF, Wang JF. Clinical observation of 24 cases of pityriasis rosea with blood deficiency and wind-dryness type treated with Dangguiyinzi modified and subtracted combined with auricular point pressure method. The Journal of Medical Theory and Practice. 2022;3:443-5.
41 Chen JH, He XY, Wang X, Qu XF. Clinical study on the treatment of wind-heat and blood-dry type pityriasis rosea with integrated traditional Chinese and western medicine. Chinese Manipulation & Rehabilitation Medicine. 2019;16:34-6.
42 Wang YQ, Bai MJ, Wu YN, Liu BX, Wang XY, Yu XJ. Research progress on diagnosis and treatment of pityriasis rosea by integrated traditional Chinese and western medicine. Shandong Journal of Traditional Chinese Medicine. 2019;4:384-9.
43 Gangemi S, Cannavo SP, Guarneri F, Merendino RA, Stur-niolo GC, Minciullo PL, et al. The CX3C-chemokine frac- talkine (CX3CL1) is detectable in serum of patients affected by active pityriasis rosea. J Eur Acad Dermatol Venereol. 2006;20:1366, 1367.
44 El-Ela MA, El-Komy M, Hay RA, Hegazy R, Sharobim A, Rashed L, et al. Higher Expression of Toll-like Receptors 3, 7, 8, and 9 in Pityriasis Rosea. Journal of Pathology and Translational Medicine. 2017;51:148-51.   DOI
45 Wagner H. The immunobiology of the TLR9 subfamily. Trends Immunol. 2004;25: 381-6.   DOI
46 Trayes KP, Savage K, Studdiford JS. Annular Lesions: Diagnosis and Treatment. Am Fam Physician. 2018;98(5):283-91.
47 Drago F, Broccolo F, Rebora A. Pityriasis rosea: an update with a critical appraisal of its possible herpesviral etiology. J Am Acad Dermatol. 2009;61:303-18.   DOI
48 Sonthalia S, Kumar A, Zawar V, Priya A, Yadav P, Srivastava S, et al. Double-blind randomized placebo-controlled trial to evaluate the efficacy and safety of short-course low-dose oral prednisolone in pityriasis rosea. J Dermatolog Treat. 2018;29(6):617-22.   DOI
49 Chuh AA. Diagnostic criteria for pityriasis rosea: A prospective case control study for assessment of validity. J Eur Acad Dermatol Venereol. 2003;17:101-3.   DOI
50 Mahajan K, Relhan V, Relhan AK, Garg VK. Pityriasis Rosea: An Update on Etiopathogenesis and Management of Difficult Aspects. Indian J Dermatol. 2016;61(4):375-84.   DOI
51 Drago F, Ciccarese G, Rebora A, Parodi A. Relapsing pityriasis rosea. Dermatology 2014;229:316-8.   DOI
52 The Minjok Medicine News. 2012[cited 2022 AUGUST 2]. Available from: URL:http://www.mjmedi.com/news/articleView.html?idxno=23863